Anti-MCAM antibody produced in rabbit

MCAM (melanoma cell adhesion molecule) is a vascular endothelium expressed cell adhesion molecule. It is ectopically expressed by malignant melanoma cells. It belongs to the immunoglobulin (Ig) superfamily. MCAM gene is a single copy gene which is localized to human chromosome 11q23, spanning 15kb and containing 16 exons. The encoded product is a transmembrane glycoprotein with a molecular weight of 113-119kDa. It is also expressed by smooth muscle cells and a subtype of activated T-cells.

Cell surface glycoprotein MUC18 precursor recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

MCAM (melanoma cell adhesion molecule) gene is linked to higher relapse probabilities in melanoma patients. It is thought to play roles in signal transduction, development, cell migration, differentiation of mesenchymal stem cells, angiogenesis and inflammatory responses. In mice, this gene is linked with tumor thickness and metastatic capabilities of human melanoma cells. The expression of this gene has potential as a prognostic marker, where the expression could correlate to poor or good outcome in melanoma patients. In late-stage osteoarthritis, this protein has potential as a marker for cartilage progenitor cell population. In gastric cancer (GC) patients, the expression of this gene is linked with lymph node metastasis and poor prognosis. Its expression is also linked to the loss of E-cadherin, and epithelial marker, and the gain of mesenchymal markers nuclear β-catenin and vimentin. Thus, in GC, this gene might be linked with epithelial-mesenchymal transition (EMT) and tumor progression.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST71658

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.